Linagliptin Does Not Increase Adverse Renal Events in Patients With T2D, Kidney Disease

Treatment with linagliptin in patients with type 2 diabetes and cardiovascular and/or kidney disease had no impact on risk for cardiovascular or kidney events.

Source: Linagliptin Does Not Increase Adverse Renal Events in Patients With T2D, Kidney Disease – Endocrinology Advisor

About the Author

NutriScape Staff